2024 EACTS guidelines on perioperative medication in adult cardiac surgery: embracing precision medicine driven by strong evidence-based methodology
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 30 March 2025
Authors
Guidelines are pivotal for optimal patient management and should be grounded by evidence-based medicine with accurate methodology.1 The European Association of Cardio-Thoracic Surgery has recently released the “2024 EACTS Guidelines on Perioperative Medication in Adult Cardiac Surgery”,2 which address significant novel advancements in the pharmacological management of adult patients undergoing various types of cardiac surgery, including open-heart surgery (coronary and non-coronary) and transcatheter aortic valve implantation. These guidelines comprise several drug classes and provide recommendations on their use, discontinuation and/or (re)introduction at the different phases surrounding elective, urgent or emergent cardiac interventions: early before, during, and after the operation, both short- and long-term. A substantial portion of the document focuses on antithrombotic agents, and several novel aspects and approaches warrant attention....
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Maria J. Fernandez Turizo, Rushad Patell, Jeffrey I. Zwicker, Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Federica Azzolini, Antonio Bruno, Ettore Dolcetti, Diego Centonze, Fabio Buttari, Tumor necrosis factor superfamily in multiple sclerosis: from pathology to therapeutic implications , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Bianca Clerici, Mariangela Scavone, Gian Marco Podda, Recent advances in classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Ettore Dolcetti, Antonio Bruno, Diego Centonze, Is transient ischemic attack a minor stroke? , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Rushad Patell, Jeffrey I. Zwicker, Rohan Singh, Simon Mantha, Machine learning in cancer-associated thrombosis: hype or hope in untangling the clot , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Juan Eirís, Marina Suárez-Terrón, Pablo Granados, David Martínez-Campuzano, Ana Rosa Cid, Saturnino Haya, Santiago Bonanad, Allopurinol-induced acquired von Willebrand syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 4 (2023)
- Mosaad Almegren, Clinical and radiological characteristics of cerebral vein thrombosis: a retrospective study , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Società Italiana per lo Studio dell'Emostasi e Trombosi - SISET, 27th SISET National Congress | Perugia, Italy, 2-5 November 2022 , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Paola Binetti, Thrombotic thrombocytopenic purpura: much done, but still a lot to do , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Paolo Prandoni, Personalized bleeding risk assessment for atrial fibrillation patients on direct oral anticoagulants: the DOAC score , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
You may also start an advanced similarity search for this article.
